



Beta-Amyloid 1-42 and 1-40 with Ratio (1-42/1-40),
Plasma

Patient ID SA00172672	Patient Name TESTING, BAMYP A		Birth Date 1990-08-08	Sex F	Age 34
Order Number SA00172672	Client Order Number SA00172672	Ordering Physician CLIENT,CLIENT	Report Notes		
Account Information C7028846 DLMP Rochester		Collected 03 Nov 2024 08:00			

Beta-Amyloid 1-42, 1-40, Ratio, P

Beta-Amyloid 1-42 Plasma

SDL

76 pg/mL

Beta-Amyloid 1-40 Plasma

SDL

1000 pg/mL

Beta-Amyloid Plasma Ratio

SDL



0.076 ratio

Reference Value ≥ 0.077

Beta-Amyloid Plasma Ratio Interpret

1 SDL

An abnormal plasma beta-Amyloid Ratio (1-42/1-40) of <0.077 is suggestive of a positive (abnormal) amyloid positron emission

tomography (PET) scan result. This result does not establish a diagnosis of Alzheimer's disease or other cognitive disorder.

The testing method is a chemiluminescent enzyme immunoassay manufactured by Fujirebio, Inc. and performed on the Lumipulse analyzer. The beta-Amyloid ratio is calculated by using individual measurements of the beta-Amyloid 1–42 and beta-Amyloid 1–40.

The Lumipulse plasma beta-Amyloid ratio (1–42/1–40) result must be interpreted in conjunction with the patient clinical information. This test is not intended as a screening or standalone diagnostic assay.

Values obtained with different assay methods or kits may be different and cannot be used interchangeably.

Received: 04 Nov 2024 09:39 **Reported:** 04 Nov 2024 10:04

Laboratory Notes

1 This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
SDL	Mayo Clinic Laboratories - Rochester Superior Drive	3050 Superior Drive NW, Rochester MN 55905	Nikola Baumann Ph.D.	24D1040592